SCHEMBL6401462

SCHEMBL6401462

O=P(O)(O)c1cc(O)ccc1CCCc1cccc(O)c1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 2/20 0.47
MGLL Q99685 1/20 0.44
DRD2 P14416 1/20 0.44
DRD1 P21728 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
HDAC6 Q9UBN7 1/20 0.43
CHRM2 P08172 2/20 0.41
CHRM1 P11229 2/20 0.41
CHRM3 P20309 2/20 0.41
OPRK1 P41145 1/20 0.40
AKR1B10 O60218 1/20 0.39
AKR1B1 P15121 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39
ENPP2 Q13822 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395755 0.97 MGLL (0.48) CALM1MGLLDRD2DRD1TAAR1
SCHEMBL6397460 0.91 DRD2 (0.46) CALM1MGLLDRD2DRD1TAAR1
SCHEMBL6401888 0.88 CALM1 (0.47) CALM1MGLLDRD2DRD1TAAR1
SCHEMBL6395874 0.86 ESR1 (0.48) CALM1MGLLCHRM2CHRM1CHRM3
SCHEMBL6396042 0.85 MGLL (0.48) CALM1MGLLDRD2DRD1TAAR1
SCHEMBL6395964 0.83 ALOX15 (0.46) MGLLCHRM2CHRM1CHRM3ENPP2
SCHEMBL6404256 0.81 SLC28A3 (0.47) CALM1MGLLDRD2DRD1TAAR1
SCHEMBL6397688 0.81 HDAC6 (0.46) MGLLDRD2DRD1TAAR1HDAC6
SCHEMBL6401455 0.79 CALM1 (0.44) CALM1MGLLDRD2DRD1TAAR1
SCHEMBL6399808 0.79 CALM1 (0.44) CALM1MGLLDRD2DRD1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 CALM1 2071/4885MGLL 3457/4885DRD2 1797/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 CALM1 2102/4885MGLL 3439/4885DRD2 1795/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 CALM1 2071/4885MGLL 3457/4885DRD2 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.